Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.7 USD | +1.32% | +1.47% | -10.46% |
Apr. 22 | Bernstein Adjusts Price Target on Illumina to $129 From $150 | MT |
Apr. 22 | Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's enterprise value to sales, at 4.4 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.46% | 19.6B | C+ | ||
+8.33% | 217B | B | ||
+6.72% | 183B | B- | ||
+10.18% | 131B | B- | ||
+24.91% | 106B | A- | ||
-0.95% | 62.16B | A- | ||
+10.56% | 51.02B | B+ | ||
+4.81% | 50.89B | B+ | ||
-0.24% | 40.16B | A | ||
+1.22% | 34.79B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ILMN Stock
- Ratings Illumina, Inc.